Forschungsprojekte
Ergebnisse pro Seite:
10
2024 - 2025
Performance Qualification des Robotersystems APOTECAunit für nicht-toxische applikationsfertiger Parenteralia- DavidAckermann,
- Prof. Dr. IreneKrämer,
- Dr. JudithThiesen
2024 - 2027
Untersuchungen zur Kompatibilität und Stabilität von ausgewählten Onkologika, insbesondere Immunonkologika- Prof. Dr. IreneKrämer,
- AnnikaNarrog,
- Dr. JudithThiesen
2023 - 2026
Cyclone 3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer- PD Dr. ReneMager,
- PD Dr. MaximilianBrandt
2023 - 2024
Mikrobiologische Performance Qualification der Robotersysteme APOTECAunit und APOTECAsyringe- Prof. Dr. IreneKrämer,
- Dr. JudithThiesen,
- DavidAckermann
2023 - 2030
Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)- Prof. Dr. med. GeorgHeß
2023 - 2024
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer- Univ.-Prof. Dr. med. MarcusSchmidt,
- Dr. KatrinAlmstedt
2022 - 2026
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle InvasiveBladder Cancer (VOLGA)- PD Dr. med. MaximilianBrandt,
- PD Dr. ReneMager,
- Dr. AnitaThomas
2022 - 2025
Kompatibilität und Stabilität von applikationsfertigen Parenteralia- Prof. Dr. IreneKrämer,
- ZoeMittmann,
- Dr. JudithThiesen
2022 - 2024
A Randomized Open Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared To Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma- Dr. med. MarkusMunder,
- Prof. Dr. med. GeorgHeß